header-logo
GettyImages-609179959-hero
Hematology and Oncology

Sun CAR-T Preclinical Research Laboratory

Dr. Fumou Sun's CAR-T Preclinical Research Laboratory focuses on advancing next-generation immunotherapies for cancer.

The primary goal of the lab is to develop superior CAR-T therapies that provide safer, more durable, and more effective treatment options for patients with relapsed and refractory cancers. Research efforts are centered on optimizing CAR T-cell and CAR-NK cell therapies to enhance therapeutic efficacy and to uncover the molecular mechanisms underlying therapy resistance.

In addition, Dr. Sun Lab is actively engaged in the development of in vivo CAR-T strategies, aiming to simplify manufacturing and broaden the accessibility of CAR-T therapy. The lab also pioneers combinatorial approaches that integrate CAR-T therapy with oncolytic virus platforms to overcome the barriers presented by the solid tumor microenvironment.

Furthermore, Dr. Sun Lab develops multifunctional antibody therapies, including antibody–drug conjugates (ADCs) and bispecific antibodies, to expand the versatility of antibody-based treatments. Through these efforts, Dr. Sun Lab strives to engineer intelligent and durable immunotherapy strategies that improve outcomes and quality of life for patients with otherwise intractable cancers.

Fumou Sun Laboratory Team

About the PI

Fumou Sun, PhDFumou Sun, PhD, is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin. His research centers on tumor immunotherapy, with a primary goal of developing superior CAR-T therapies to provide safer, more durable, and more effective treatment options for relapsed and refractory cancers. His work also extends to in vivo CAR-T strategies, aiming to simplify manufacturing processes and broaden access to CAR-T therapy. In addition, he investigates combinatorial approaches with oncolytic viruses to overcome barriers posed by the solid tumor microenvironment and develops multifunctional antibody therapies such as antibody–drug conjugates (ADCs) and bispecific antibodies.

Dr. Sun earned his PhD from China Pharmaceutical University in 2019 and completed seven years of advanced research training in tumor genetics and immunotherapy at the University of Iowa, the Medical College of Wisconsin, and the University of Arkansas for Medical Sciences. He returned to MCW in 2024, where he collaborates closely with clinical colleagues to accelerate the translation of next-generation immunotherapies. He currently leads multiple funded projects and holds several patent applications. His research has been published in over 30 high-impact journals, including The Journal of Clinical Investigation (JCI), Nature Communications, and Cancer Research. Dr. Sun has received numerous prestigious awards, including the 24th Annual ECOG-ACRIN Young Investigator Award, the American Society of Hematology (ASH) Abstract Achievement Awards in 2022 and 2023, the Young Investigator Award at the 17th International Myeloma Workshop (IMW), and the Scholar-in-Training Award from the American Association for Cancer Research (AACR).

Learn more about Dr. Sun

Current Members

headshot

Shijing Wang, PhD

Postdoctoral Researcher

headshot

Bin Sun, BS

Project Appointment Student

headshot

Ali Ishaq, BS

UWM–MCW Fellowship Student

Contact Us

Sun CAR-T Preclinical Research Laboratory
(414) 955-2117 | fsun@mcw.edu

Recent Publications

Publications of Fumou Sun PhD from the Faculty Collaboration Database

© 2025 Medical College of Wisconsin.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The Medical College of Wisconsin (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. MCW maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

MCW's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.